Anat Fisher1, Greg Carney2, Ken Bassett2,3, Colin R Dormuth2. 1. Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. anat.fisher@ti.ubc.ca. 2. Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. 3. Department of Family Medicine, University of British Columbia, 5950 University Boulevard, Vancouver, BC, V6T 1Z3, Canada.
Abstract
BACKGROUND: Cholinesterase inhibitors (ChEIs) are prescribed to dementia patients despite their poor tolerance. Low tolerability potentially reduces persistence and adherence, while inducing switching between medications. Comparisons of these utilization measures contribute to knowledge of the relative tolerability of these medications. AIM: The aim was to compare persistence, adherence, and switching between donepezil, galantamine, oral rivastigmine, and rivastigmine patch. METHODS: A population-based cohort study, using British Columbia claims data (2009-2013), assessed ChEI new users aged 40 and older. We conducted survival analysis to compare persistence and Poisson regression to estimate switching rates. Good adherence, defined as a medication possession ratio of ≥80%, was modeled using log-binomial regression. Analyses were adjusted using propensity scores. RESULTS: Patients on galantamine had longer mean persistence and better adherence compared with patients on donepezil, with a hazard ratio for discontinuation of 0.91 [95% confidence interval (CI) 0.87-0.96] and a relative risk for good adherence of 1.01 (95% CI 1.002-1.03). Rivastigmine was associated with the shortest mean persistence [3.6 months (95% CI 3.0-4.2) and 5.0 (95% CI 4.7-5.3) for oral and patch, respectively] and the highest mean switching rates. Comparing the two rivastigmine preparations, the patch was associated with decreased discontinuation compared with oral [hazard ratio 0.79 (95% CI 0.71-0.89)] and decreased switching [relative risk 0.63 (95% CI 0.46-0.87) during the first 6 months of treatment]. Paradoxically, the patch was also associated with poorer adherence [relative risk for good adherence 0.94 (95% CI 0.91-0.98)] than the oral formulation. CONCLUSIONS: Based on estimates of persistence, adherence, and switching, galantamine was the best tolerated ChEI and rivastigmine the least.
BACKGROUND:Cholinesterase inhibitors (ChEIs) are prescribed to dementiapatients despite their poor tolerance. Low tolerability potentially reduces persistence and adherence, while inducing switching between medications. Comparisons of these utilization measures contribute to knowledge of the relative tolerability of these medications. AIM: The aim was to compare persistence, adherence, and switching between donepezil, galantamine, oral rivastigmine, and rivastigmine patch. METHODS: A population-based cohort study, using British Columbia claims data (2009-2013), assessed ChEI new users aged 40 and older. We conducted survival analysis to compare persistence and Poisson regression to estimate switching rates. Good adherence, defined as a medication possession ratio of ≥80%, was modeled using log-binomial regression. Analyses were adjusted using propensity scores. RESULTS:Patients on galantamine had longer mean persistence and better adherence compared with patients on donepezil, with a hazard ratio for discontinuation of 0.91 [95% confidence interval (CI) 0.87-0.96] and a relative risk for good adherence of 1.01 (95% CI 1.002-1.03). Rivastigmine was associated with the shortest mean persistence [3.6 months (95% CI 3.0-4.2) and 5.0 (95% CI 4.7-5.3) for oral and patch, respectively] and the highest mean switching rates. Comparing the two rivastigmine preparations, the patch was associated with decreased discontinuation compared with oral [hazard ratio 0.79 (95% CI 0.71-0.89)] and decreased switching [relative risk 0.63 (95% CI 0.46-0.87) during the first 6 months of treatment]. Paradoxically, the patch was also associated with poorer adherence [relative risk for good adherence 0.94 (95% CI 0.91-0.98)] than the oral formulation. CONCLUSIONS: Based on estimates of persistence, adherence, and switching, galantamine was the best tolerated ChEI and rivastigmine the least.
Authors: Bengt Winblad; Ariane K Kawata; Kathleen M Beusterien; Simu K Thomas; Anders Wimo; Roger Lane; Howard Fillit; Rafael Blesa Journal: Int J Geriatr Psychiatry Date: 2007-05 Impact factor: 3.485
Authors: G Lefèvre; G Sedek; S S Jhee; M T Leibowitz; H-La Huang; A Enz; S Maton; L Ereshefsky; F Pommier; H Schmidli; S Appel-Dingemanse Journal: Clin Pharmacol Ther Date: 2007-05-23 Impact factor: 6.875
Authors: Haesuk Park; Karen L Rascati; Kenneth A Lawson; Jamie C Barner; Kristin M Richards; Daniel C Malone Journal: J Manag Care Spec Pharm Date: 2014-08
Authors: R Blesa González; M Boada Rovira; C Martínez Parra; D Gil-Saladié; C A Almagro; A L Gobartt Vázquez Journal: Neurologia Date: 2011-01-11 Impact factor: 3.109
Authors: Oliver Schwalbe; Christian Scheerans; Ines Freiberg; Andrea Schmidt-Pokrzywniak; Andreas Stang; Charlotte Kloft Journal: BMC Health Serv Res Date: 2010-08-09 Impact factor: 2.655
Authors: Serge Gauthier; Christopher Patterson; Howard Chertkow; Michael Gordon; Nathan Herrmann; Kenneth Rockwood; Pedro Rosa-Neto; Jean-Paul Soucy Journal: Can Geriatr J Date: 2012-12-04
Authors: Jamie L Fleet; Eric McArthur; Aakil Patel; Matthew A Weir; Manuel Montero-Odasso; Amit X Garg Journal: CMAJ Date: 2019-09-16 Impact factor: 8.262
Authors: Greg Carney; Ken Bassett; James M Wright; Malcolm Maclure; Nicolette McGuire; Colin R Dormuth Journal: Alzheimers Dement (N Y) Date: 2019-11-25